PTC Therapeutics

PTC Therapeutics’ cancer stem cell program targeting BMI1 enters phase I

Thursday, April 30, 2015

PTC Therapeutics has announced that its oncology program targeting BMI1, a protein linked to drug-resistant cancers, has entered a phase I study in patients with advanced solid tumors. The open-label, first-in-human study will investigate the safety and pharmacokinetics of PTC596, an orally available small molecule. PTC’s BMI1 program is supported by a collaboration with the Wellcome Trust.

[Read More]

PTC Therapeutics, University of Pennsylvania collaborate on orphan disease research

Thursday, March 19, 2015

PTC Therapeutics, a global biopharmaceutical company, has inked a collaboration with the Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania focused on translational research for discovering and developing new treatments for orphan disorders. The partnership reflects both parties’ commitment to developing treatments and improving the lives of those who suffer from rare diseases.

[Read More]

Spinal muscular atrophy program enters phase Ib/IIa trial in patients with SMA

Thursday, November 20, 2014

PTC Therapeutics’ joint development program in spinal muscular atrophy (SMA) with Roche and the SMA Foundation (SMAF) has started a phase Ib/IIa study in adult and pediatric patients. The placebo-controlled, randomized, multiple-dose study will enroll approximately 48 patients with SMA and investigate the safety and tolerability of an investigational survival of motor neuron 2 (SMN2) gene splicing modifier (RG7800) over 12 weeks. The achievement of this milestone triggers a $10 million payment to PTC from Roche.

[Read More]

PTC Therapeutics expands management team

Monday, January 27, 2014

PTC Therapeutics has expanded its senior management team with the appointment of Robert J. Spiegel, M.D., FACP, to chief medical officer and Murad Husain to vice president, Global Regulatory Affairs. PTC also announced the promotions of Joseph Colacino, Ph.D., to senior vice president, Drug Discovery and Ernest R. Dietel to senior vice president, Quality. In addition, Jay Barth, M.D., senior vice president of Clinical Development, is leaving PTC to pursue other opportunities.

[Read More]

PTC Therapeutics, the SMA Foundation and Roche collaborate

Friday, January 24, 2014

PTC Therapeutics, the SMA Foundation and Roche have announced that their joint research program in Spinal Muscular Atrophy (SMA) has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers. SMA is a genetic neuromuscular disorder that leads to muscle weakness and mobility impairment and is considered the leading genetic cause of death in infants and toddlers.

[Read More]